SSStephen E. Straus

Stephen E. Straus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen E. Straus has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Janet K. Dale

    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

    4 shared publications
  • Jennifer M. Puck

    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

    4 shared publications
  • Elaine S. Jaffe

    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

    3 shared publications
  • Janet K. Dale

    Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

    3 shared publications
  • Warren Strober

    From the Laboratory of Clinical Investigation, Clinical Research Training Program, and Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Laboratory of Pathology, National Cancer Institute, National Human Genome Research Institute, and Clinical Pathology Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland; and SAIC, Inc, Frederick, Maryland

    3 shared publications
  • Faith Dugan

    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

    2 shared publications

Latest Publications

  • Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS)

    by V. Koneti Rao, Jorge A. Carrasquillo, Janet K. Dale, Stephen L. Bacharach, Millie Whatley, Faith Dugan, Jean Tretler, Thomas Fleisher, Jennifer M. Puck, Wyndham Wilson, et al.

    Autoimmune lymphoproliferative syndrome (ALPS) is associated with mutations that impair the activity of lymphocyte apoptosis proteins, leading to chronic lymphadenopathy, hepatosplenomegaly, autoimmunity, and an increased risk of lymphoma. We investigated the utility of fluorodeoxyglucose positron emission tomography (FDG‐PET) in discriminating benign from malignant lymphadenopathy in ALPS. We report that FDG avidity of benign lymph nodes in ALPS can be high and, hence, by itself does not imply presence of lymphoma; but FDG‐PET can help guide the decision for selecting which of many enlarged nodes in ALPS patients to biopsy when lymphoma is suspected. Am. J. Hematol. 81:81–85, 2006.


  • Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome

    by V. Koneti Rao, Faith Dugan, Janet K. Dale, Joie Davis, Jean Tretler, John K. Hurley, Thomas Fleisher, Jennifer Puck, Stephen E. Straus

    Summary: Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of apoptosis associated most often with heritable FAS mutations leading to lymphadenopathy, hypersplenism and chronic refractory autoimmune cytopenias. Mycophenolate mofetil (MMF) was used to treat cytopenias in 13 ALPS patients aged 9 months to 17 years from a cohort of 118 children (aged < 18 years) and 82 adults. Twelve responded for a median follow‐up of 49 weeks (range 38–240 weeks), defined by maintenance of adequate blood counts and reduction in dosage or cessation of other immunosuppressive agents. This preliminary experience suggests that MMF may spare steroid usage in patients with ALPS‐associated cytopenias.


  • Open Access

    St. John's Wort: more implications for cancer patients.

    by Patrick J. Mansky, Stephen E. Straus

    St. John's wort (Hypericum perforatum L.) has been used as a medicinal plant in Europe and Asia for centuries. Although it is best known today for its use by patients with mild to moderately severe depression, St. John's wort has also been used orally as a traditional treatment for excitability, neuralgia, fibrositis, sciatica, and anxiety and as a topical preparation for the treatment of wounds (1). Concerns over its use have been raised with the recognition that, whatever its beneficial health effects might be, St. John's wort interacts powerfully with many important drugs, potentially mitigating their effects (1).


  • Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice

    by Sarat K. Dalai, Lesley Pesnicak, Georgina F. Miller, Stephen E Straus

    Pooled human immunoglobulin (IgG) was evaluated as prophylaxis and treatment of HSV-1 infection in mice. We compared the effects of IgG on the course of acute infection and spread of virus through...


  • Top Cited Papers

    The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis

    by Stephen E. Straus, Elaine S. Jaffe, Jennifer M. Puck, Janet K. Dale, Keith B. Elkon, Angela Rösen-Wolff, Anke M. J. Peters, Michael C. Sneller, Claire W. Hallahan, Jin Wang, et al.

    Lymphomas were studied in kindreds with autoimmune lymphoproliferative syndrome (ALPS; Canale-Smith syndrome), a disorder of lymphocyte homeostasis usually associated with germline Fas mutations. Fas (CD95/APO-1) is a cell surface receptor that initiates programmed cell death, or apoptosis, of activated lymphocytes. Lymphoma phenotype was determined by immunohistochemistry, frequency of CD3+CD4−CD8− T-cell–receptor α/β cells by flow cytometry, nucleotide sequences of the gene encoding Fas ( APT1 , TNFRSF6), and the percentage of lymphocytes undergoing apoptosis in vitro. Of 223 members of 39 families, 130 individuals possessed heterozygous germline Fas mutations. Eleven B-cell and T-cell lymphomas of diverse types developed in 10 individuals with mutations in 8 families, up to 48 years after lymphoproliferation was first documented. Their risk of non-Hodgkin and Hodgkin lymphomas, respectively, was 14 and 51 times greater than expected (each P < .001). Investigation of these 10 patients and their relatives with Fas mutations revealed that all had defective lymphocyte apoptosis and most had other features of ALPS. The tumor cells retained the heterozygous Fas mutations found in the peripheral blood and manifested defective Fas-mediated killing. These data implicate a role for Fas-mediated apoptosis in preventing B-cell and T-cell lymphomas. Inherited defects in receptor-mediated lymphocyte apoptosis represent a newly appreciated risk factor for lymphomas.


  • Open Access

    Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression

    by Uri Lopatin, Xu Yao, Richard K. Williams, Jack J. H. Bleesing, Janet K. Dale, David Wong, Julie Teruya-Feldstein, Scott Fritz, Matthew R. Morrow, Ivan Fuss, et al.

    Autoimmune lymphoproliferative syndrome (ALPS) is an inherited disorder in which genetic defects in proteins that mediate lymphocyte apoptosis, most often Fas, are associated with enlargement of lymph nodes and the spleen and a variety of autoimmune manifestations. Some patients with ALPS have relatives with these same apoptotic defects, however, who are clinically well. This study showed that the circulating levels of interleukin 10 (IL-10) were significantly higher (P < .001) in 21 patients with ALPS than in healthy controls. Moreover, the peripheral blood mononuclear cells (PBMCs) and lymphoid tissues of these patients with ALPS contained significantly higher levels of IL-10 messenger RNA (mRNA;P < .001 and P < .01, respectively). By fractionating PBMC populations, disproportionately high concentrations of IL-10 mRNA were found in the CD4−CD8−T-cell population, expansion of which is virtually pathognomonic for ALPS. Immunohistochemical staining showed intense IL-10 protein signals in lymph node regions known to contain CD4−CD8− T cells. Nonetheless, in vitro studies showed no influence of IL-10 on the survival of CD4−CD8− T cells. Overexpression of IL-10 in patients with inherited apoptotic defects is strongly associated with the overt manifestations of ALPS.


  • Gamma Interferon Impedes the Establishment of Herpes Simplex Virus Type 1 Latent Infection but Has No Impact on Its Maintenance or Reactivation in Mice

    by Julie A. Lekstrom-Himes, Rona A. LeBlanc, Lesley Pesnicak, Matthew Godleski, Stephen E. Straus

    Murine models of gamma interferon (IFN-γ) deficiency demonstrate the role of this cytokine in attenuating acute herpes simplex virus (HSV) disease; however, the effect of IFN-γ on the establishment and maintenance of neuronal latency and viral reactivation is not known. Using the IFN-γ knockout (GKO) model of IFN-γ deficiency and sensitive quantitative PCR methods, we show that IFN-γ significantly reduces the ganglion content of latent HSV-1 in BALB/c mice, which in turn delays viral time to reactivation following UV irradiation. Similar effects were not seen in the C57BL/6 strain. These results indicate that IFN-γ significantly attenuates latent HSV infection in the mouse model of ocular infection but has no impact on the maintenance of latency or virus reactivation.


  • Complementary and Alternative Medicine

    by S E Straus

    The objective of medicine is to address people's unavoidable needs for emotional and physical healing. The discipline has evolved over millennia by drawing on the religious beliefs and social structures of numerous indigenous peoples, by exploit- ing natural products in their environments, and more recently by developing and validating therapeutic and preventive approaches using the scientific method. Public health and medical practices have now advanced to a point at which people can anticipate—and even feel entitled to—lives that are longer and of better quality than ever before in human history. Yet despite the pervasiveness, power, and promise of con- temporary medical science, large segments of humanity either cannot access its benefits or choose not to do so. More than 80 percent of people in developing nations can barely afford the most basic medical procedures, drugs, and vaccines. In the industrial nations, a surprisingly large proportion of people opt for practices and products for which proof as to their safety and efficacy is modest at best, practices that in the aggregate are known as complementary and alternative medicine (CAM) or as traditional medicine (TM). Much of this book considers the formidable challenges to advancing human health through the further dispersion of effective and economical medical practices. This chapter con- siders both proven and unproven but popular CAM and TM approaches and attempts to portray their current and potential place in the overall practice of medicine. With globalization, the pattern of disease in developing countries is changing. Unlike in the past, when communica- ble diseases dominated, now 50 percent of the health burden in developing nations is due to noncommunicable diseases, such as cardiovascular diseases, diabetes, hypertension, depression, and use of tobacco and other addictive sub- stances. Because lifestyle, diet, obesity, lack of exercise, and stress are important contributing factors in the causation of these noncommunicable diseases, CAM and TM approaches to these factors in particular will be increasingly important for the development of future health care strategies for the developing world.


  • Sensitivity to Chemical Exposure Questionnaire

    by Stefan S. Nawab, Claudia S. Miller, Janet K. Dale, Benjamin D. Greenberg, Theodore C. Friedman, George P. Chrousos, Stephen E. Straus, Norman E. Rosenthal